Epitope mapping of an antihuman EGFR monoclonal antibody (EMab-134) using the REMAP method

Masato Sano, Mika K. Kaneko, Teizo Aasano, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays an important role in normal epidermal cell physiology. EGFR is overexpressed in cancer cells and has a number of mutations that implicate tumor malignancy, development, and poor patient prognosis; thus, EGFR is an attractive target for cancer therapy. At present, anti-EGFR monoclonal antibodies (mAbs) have been approved and are used for treating patients with a variety of EGFR-expressing cancers. Epitope mapping is important in identifying the therapeutic mechanism of anti-EGFR mAbs; however, the development of epitope mapping techniques lags behind the development of antimolecular target mAbs, including anti-EGFR mAbs. Hence, in this study, a novel epitope mapping method, RIEDL insertion for epitope mapping (REMAP) method, was developed. The results of this study demonstrated that the critical epitope of anti-EGFR mAb EMab-134 is Gly378, Asp379, Ser380, Phe381, Thr382, His383, Thr384, Pro385, and Pro386 of EGFR. The REMAP method could be useful for determining the critical epitope of functional mAbs against many target molecules.

Original languageEnglish
Pages (from-to)191-195
Number of pages5
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Issue number4
Publication statusPublished - 2021 Aug 1


  • EGFR
  • EMab-134
  • epitope mapping
  • monoclonal antibody
  • RIEDL tag


Dive into the research topics of 'Epitope mapping of an antihuman EGFR monoclonal antibody (EMab-134) using the REMAP method'. Together they form a unique fingerprint.

Cite this